Report Unveils Region’s Position Among Other BioHealth/Tech Hotbeds Across the Country as Local Leaders Drive Towards Placement as Top Biotech Hub by 2023
The Economic Alliance of Greater Baltimore (EAGB) and BioHealth Innovation, Inc. (BHI) officially released the BioHealth Innovation Index for Central Maryland at the Second Annual Regional BioTech Forum, which took place April 18 and 19 in Gaithersburg, Maryland. The Index is a comprehensive analysis of the biohealth industry highlighting the region’s strengths, along with those areas that present opportunity for economic growth.
The Index will serve as a guide for the continued development of Maryland’s booming biohealth region, by pinpointing key opportunities for future growth to accelerate the region to the top three biotech hubs in the U.S. by 2023.
According to BHI CEO Rich Bendis, who also serves on the Governor of Maryland’s Life Sciences Advisory Board, “This index both confirms the region’s standing, while also shedding light on what it will take to raise our spot among the top three biotech/biohealth hotbeds in the country. Our region is attracting new and innovative companies at unprecedented speeds. This Index reflects such innovation occurring in Greater Baltimore and Central Maryland, and provides a platform on which to develop a strategic analysis relevant to other U.S. markets such as Boston, New York, Philadelphia, Pittsburgh, Raleigh-Durham, San Diego and San Francisco.”
A new report by the Economic Alliance of Greater Baltimore and BioHealth Innovation Inc. says Maryland must pick up the pace on entrepreneurship to be the national leader in biohealth
The NIH is the premier biomedical research center for the world. Its 27 Institutes and Centers employ approximately 18,000 employees doing a vast array of jobs, all supporting efforts for a healthy nation. For information on the NIH mission, goals, and Institutes and Centers, visit NIH Overview
This position is located in the Technology Transfer Center (TTC) of the National Cancer Institute (NCI), National Institutes of Health (NIH). The Technology Transfer Center of the National Cancer Institute is seeking exceptional, dynamic candidates for the Invention Development and Marketing Supervisor. The Supervisor will mentor, empower and lead the newly formed Invention Development and Marketing Unit, and drive the strategy to accelerate and increase the volume of NCI inventions matched with partners who can commercialize federal inventions to improve public health. The ideal candidate will have an understanding of research and development in a federal setting, but bring the mindset and energy of an entrepreneur to lead the team, please visit http://ttc.nci.nih.gov/.
Gov. Larry Hogan called the state’s life sciences industry the “backbone of Maryland’s economy” and said the state must do more to drive new business here.
Hogan spoke at the close of the first day of the BioHealth Capital Region Forum, a two-day event taking place at MedImmune’s Rockville headquarters Monday and Tuesday.
Everyone knows what Silicon Valley and Research Triangle Park are. What about the BioHealth Capital Region?
That’s how MedImmune and a collection of regional stakeholders say Greater Washington should brand itself to better promote its biotech and life sciences industry. The name was introduced Monday as part of the BioHealth Capital Region forum at MedImmune headquarters in Gaithersburg.
MedImmune has introduced the phrase “BioHealth Capital Region” to brand Greater Washington’s biotech and life sciences sectors and hopes the name will grow organically.
More than 700 leaders from life science companies, academic institutions, nonprofit organizations, investment funds and government entities across Maryland, Virginia and Washington, D.C. (MD-VA-DC) will convene today and tomorrow for the second annual Regional BioTech Forum. The event will showcase the region’s biotechnology accomplishments and its commitment to advancing cutting-edge research in the MD-VA-DC corridor. Notable speakers will include: Dr. Francis Collins, Director, National Institutes of Health; Maryland Governor Larry Hogan; Virginia Governor Terry McAuliffe; and Congressman John Delaney.
Lazy is a small, Rockville, Md.-based startup that competes in the extremely lucrative healthcare IT market, which is poised to be valued in excess of $228 billion by 2020 according to MarketsandMarkets. Co-founded by Chris Millet, Bobby Jones and Dolly Singh, the small company recently graduated from the newly established Relevant Health business accelerator.
The Big Idea CONNECTpreneur Forum is a Community of over 3500 Business leaders, CEOs, Entrepreneurs, VCs and angels in the Mid-Atlantic Region.
Each quarterly CONNECTpreneur Forum mashes up 350+ top founders, angels, CXOs, VCs, and business leaders for a morning breakfast event featuring awesome networking, newsmaking speakers, and a showcase of 6-7 exciting companies.
This UNIQUE EVENT is like NONE OTHER in our region, due to the high quality of our attendees and participants, as well as our programming and unprecedented networking.
QIAGEN N.V. today announced introduction of its unique RNA-seq Explorer Solution, a bioinformatics-driven approach to analysis and interpretation of “omics” data from liquid biopsy-based research. RNA-seq Explorer Solution is a new tool which integrates Ingenuity® Pathway Analysis™, Biomedical Genomics Workbench® and other QIAGEN bioinformatics solutions to generate clear insights for research into improved detection, diagnosis and treatment of cancer. The solution will be demonstrated at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans.
Baltimore-area companies accounted for eight of the 10 biggest venture capital deals in the state during the first quarter of 2016.
Maryland companies raised a total of $109.8 million in 19 deals during the first quarter, up from $97 million invested in 14 deals the same quarter last year, according to a MoneyTree Report by PricewaterhouseCoopers and the National Venture Capital Association, based on data from Thomson Reuters. The amount invested in Maryland is up 13 percent and the number of deals is up 36 percent, compared to the year-ago quarter.
Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s lead product, Epi proColon® , the first and only FDA-approved blood-based colorectal cancer screening test.
TriFusion Devices from Texas A&M University emerged as the top startup company in the Rice Business Plan Competition (RBPC) tonight at Rice University’s Jones Graduate School of Business. The annual event is the world’s richest and largest student startup competition.
Selected by 275 judges from the investment sector as representing the best investment opportunity and taking home nearly $400,000 in cash and prizes, TriFusion Devices bested 41 other competitors hailing from some of the world’s top universities. TriFusion Devices offers breakthrough 3-D printed products and services aimed at revolutionizing the health care and sports-equipment industries in powerful and profitable ways.
Significant new prizes this year and the teams that won them include the following:
* $25,000 Rice Brown School of Engineering Tech Innovation Prize – Leuko, Massachusetts Institute of Technology.
* $100,000, Cisco Internet of Everything Innovation Challenge Prize – Neopenda, Columbia University.
Ahead of the Johns Hopkins Social Innovation Lab’s Impact and Innovation Forum on April 21, we’re profiling the entrepreneurs that are part of the current cohort.
Here’s a look at three startups focused on building health solutions in Baltimore:
Register to attend the Celebration of Innovation and Partnerships at the University of Maryland
When: May 9, 2016 Time: 4:00-6:00 pm Where: Orem Hall, Riggs Alumni Center, University of Maryland
These new inventions will be honored at a special Celebration of Innovation and Partnerships event on May 9 as part of the University of Maryland’s “30 Days of EnTERPreneurship.” Each year, UMD honors exceptional inventions that have the potential to make an important impact on science, society, and the free market. The Invention of the Year award nominees come from three categories: Physical Sciences, Life Sciences, and Information Sciences. One invention from each category is selected to win the Invention of the Year Award.
Partnerships with private corporations can be valuable for universities looking to speed up the process of translating academic research to commercial products, services and companies.
In a commentary published today by Bloomberg View, Johns Hopkins University President Ronald J. Daniels calls attention to increasing strain being placed on America’s public research universities, a fact that Daniels says has left them less well positioned to fulfill their traditional missions.
Each spring Johns Hopkins honors exceptional graduate students and postdoctoral fellows at the annual Young Investigators’ Day celebration. The day is meant to celebrate the achievement and hard work of not only the award winners, but of all Johns Hopkins’ research trainees. This year two BME PhD candidates and a BME MD PhD candidate were selected to receive distinguished awards. The awards, named after notable researchers, including many who were former faculty members or graduate students at The Johns Hopkins University, were granted in recognition of outstanding research
Precision for Medicine, part of the Precision Medicine Group, announced today that it has executed a binding agreement to acquire ACT Oncology, the leading contract research organization (CRO) specializing exclusively in the field of oncology. ACT Oncology provides drug development services focused on the design and execution of clinical trials on behalf of innovative life sciences companies and not-for-profit patient organizations.
Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals Inc. has launched its Donepezil Hydrochloride Tablets, 23 mg having received approval from the United States Food and Drug Administration (FDA) earlier to market a generic equivalent of Eisai Inc’s Aricept® Tablets, 23mg.
This ranking is based on eight metrics, organized into four categories: concentration, which is the number of software developers per 1,000 workers in the metro area; prosperity, as measured by the regional price parity-adjusted average salary for developers in the area, the growth of wages from 2010-14, and job growth over the same span; talent, based on the number computer science degrees awarded per 10,000 workers, the percentage of of the over-25 population with computer or math degrees, and the replacement rate of IT degree holders in 2014; and the amount of venture capital investment per employee in 2015. Concentration received a 30% weighting with the remaining seven factors being equal at a 10% weighting. The study was conducted by BW Research Partnership for the San Diego Regional Economic Development Corp.
Montgomery County Department of Economic Development has played an active role in the cultivation of new and innovative technologies developed in federal laboratories and academia, known as technology transfer.
Chris Vizas, Chairman of SmartSenseCom, Inc., wraps up DED’s Tech Transfer Speakers Series The term “technology transfer” entered the public lexicon in 1986 through the Technology Transfer Act. This vehicle gave promise to millions of scientists and entrepreneurs who wanted to work with these innovative and sometimes disruptive technologies to commercialize them and bring them to the marketplace.
Cydan Development, Inc. raised $31 million in Series A funding from New Enterprise Associates, Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments. Cydan raised the capital to launch Imara, Inc., which is developing treatment for sickle cell disease.
The Tom Tom Founders Festival held a Youth Summit at the Paramount Theater Thursday to support and highlight local student innovation.
The summit featured student-led presentations and several student entrepreneurial competitions. Wes Bellamy, vice-mayor of Charlottesville, gave the keynote address, and Virginia Gov. Terry McAuliffe signed a bill to protect the rights of student innovators.
Maryland legislators recently approved a $42.3 billion fiscal year 2017 spending bill that incorporates many of the funding levels included in Gov. Larry Hogan’s proposal. Gov. Hogan made education a main focus of his proposal, and the final bill would hold university tuition increases to no more than 2 percent. In addition, legislators formalized the growing strategic partnership between University of Maryland campuses in Baltimore and College Park. The unification is intended to bolster the state’s research profile, and drive high-tech industries in the Baltimore region.
Cancer doctor Cassian Yee remembers how in 2010 he was called to Los Angeles to meet the Internet billionaire Sean Parker. Parker wanted Yee to help the Hollywood producer Laura Ziskin, then fighting breast cancer, with an immune-cell treatment never before used to treat that condition. “We’ll give you whatever you need, we’ll put you on an island to do it,” Parker told Yee. A few weeks later a very big check arrived by mail to buy some crucial equipment.
SBIR/STTR programs are the nation’s largest source of early stage / high risk R&D funding for small business. At this conference you’ll learn how to participate and compete for funding in these two programs that encourage small businesses to engage in Federal Research/Research and Development (R/R&D) and to commercialize your technological innovations.
The fastest-growing sector in Greater Washington is business and financial services jobs, which grew by 39 percent between 2003 and 2014. And nearly 1 in 12 jobs in the region in 2014 was in information technology.
Illumina is committing $100 million over 10 years to a new venture capital firm whose investment priorities will be in line with the company’s vision.
Illumina said the new firm—to be called Illumina Ventures—will be managed independently of the sequencing giant. However, Illumina will be the majority limited partner in the firm’s first fund as a result of its commitment.
The Washington, D.C. mayor has called for a vote this year on statehood for the nation’s capital.
Speaking Friday at an event commemorating the district’s emancipation from slavery, D.C. Mayor Muriel Bowser said, “I propose we take another bold step toward democracy in the District of Columbia,” according to the Washington Post. “It’s going to require that we send a bold message to the Congress and the rest of the country, that we demand not only a vote in the House of Representatives. We demand two senators—the full rights of citizenship in this great nation.”
You probably know Steve Case best as the man responsible for America Online. But two decades later, Case is continuing the charge to help the new generation of technology and business leaders define the critical path of Internet and innovation to become much more useful to society.
Nearly 50 new medicines are projected to be launched each year by 2020, a new report from the IMS Institute for Healthcare Informatics says. As such, a number of new drug brands will be available on the market. The majority, unsurprisingly, will be designed to treat cancer.
Much has been made of China’s efforts to close the gap between western high technology sectors, and in the case of certain spaces, to actually bridge the gap and become a global leader. In form, these efforts represent the potential – but not the inevitability – of similar outcomes in other high technology sectors. One of the sectors that has received significant interest by the Chinese government are life sciences; however, as we found in a nearly two year survey of various Chinese officials, entrepreneurs and multinationals, the unique requirements to re-create the innovative ecosystem for the life science space remain immature in China. While the potential for China to disrupt how and where life science innovation takes place globally, there are reasons to believe the country’s policies to develop domestic success stories may fall short of similar endeavors in other high technology segments such as clean-technology.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
